|
蓝芩口服液治疗放射性咽喉炎的疗效和安全性 |
| |
【摘要】 目的 观察蓝芩口服液治疗放射性咽喉炎的疗效和安全性。方法 本院住院的恶性肿瘤患者148例，男81例，女67例，年龄31~87岁。均为经病理或细胞学检查确诊的恶性肿瘤，放疗后出现咽部不适等症状，诊断为放射性咽喉炎。按随机数字表法分为两组：治疗组100例和对照组48例。治疗组给予蓝芩口服液（扬子江药业集团生产，主要成分为板蓝根、黄芩、栀子、胖大海、黄柏，国药准字Z19991005）10 ml，3次/d。对照组给予雾化吸入、止痛等对症治疗。两组均以1周为1疗程，观察1疗程。结果 治疗组治愈率、总有效率显著高于对照组（分别为χ2=4.896，χ2=4.128，P均<0.01）。治疗组咽痛、咽部充血、咽喉壁黏膜干燥、萎缩消失时间明显短于对照组（P均<0.05）。结论 蓝芩口服液治疗放射性咽喉炎安全、有效。
【关键词】 放射性咽喉炎；临床疗效研究；蓝芩口服液
Abstract： Objective To observe the therapeutic effect of Lanqin oral solution on radiation laryngopharyngitis and its safety. Methods A total of 148 inpatients with malignant tumor were enrolled from the department of Traditional Chinese Medicine (TCM), PLA General Hospital. There were 81 males and 67 females aged from 31 to 87 years. All the patients were diagnosed as malignant tumor by pathological or cytological examination, and were then diagnosed as radiation laryngopharyngitis after radiotherapy. Furthermore, they were divided into two groups at random, i.e. trial group (n=100) and control group (n=48). The trial group were treated with Lanqin oral solution (10 ml, thrice per day), which was produced by Yangtze River Pharmacy Group Co. Ltd. The main constituents were isatis root, scutellaria, gardenia, boatfruited sterculia, and cortex phellodendri. The control group was treated with heteropathy. Both the groups were treated for one week as a cycle of treatment. Results (1) The overall response rate of the trial group was higher than that of the control group (χ2=4.896, χ2=4.128, P<0.01). (2) The time, within which the clinical symptoms and signs disappeared, was shorter in the trial group than in the control group (P<0.05). Conclusion Lanqin oral solution is safe and effective on radiation laryngopharyngitis. It is worth spreading clinically.
Key words： radiation laryngopharyngitis; lanqin oral solutions; clinical effect
放疗为许多发生于上半身的恶性肿瘤（如甲状腺癌、肺癌、食管癌、乳腺癌、鼻咽癌、腮腺癌、颈部淋巴结转移癌等）的主要治疗手段之一，在治疗过[1] [2] [3] 下一页
上一个医学论文： 总结面听神经根压迫综合征48例的手术治疗经验
下一个医学论文： 大学生抑郁症的主要临床表现及治疗
|
|
|
|
|
|
|
您现在的位置： 绿色健康网 >> 医学论文 >> 儿科论文 >> 正文